FV-100

FV-100
FV-100
IUPAC name
3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2-one
Other names
Cf1743
Identifiers
PubChem 493485
Jmol-3D images Image 1
Properties
Molecular formula C22H26N2O5
Molar mass 398.45 g mol−1
 YesY (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug[1] with antiviral activity.[2] It may be effective against shingles.[3]

It was discovered in 1999.[4]

Clinical trials

It is in a phase II trial against valaciclovir in patients with herpes zoster.[5]

References

  1. ^ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009, http://www.medicalnewstoday.com/articles/138537.php 
  2. ^ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595. 
  3. ^ , 2010, http://www.dailymail.co.uk/health/article-515969/Thousands-spared-pain-shingles.html, ""And at Cardiff University, Chris McGuigan, professor of medicinal chemistry, has developed a new drug for shingles, FV-100, which is doing well in phase I trials. FV 100 looks like it will be very potent (more than 10,000 times as strong as aciclovir), safe and could prevent long-term pain, too. It could be on the market by 2010."" 
  4. ^ Step forward for shingles drug - FV100, http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html  Shows structure of FV100
  5. ^ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, http://clinicaltrials.gov/ct2/show/NCT00900783 


Stub icon This antiinfective drug article is a stub. You can help Wikipedia by expanding it.